EP0406279A1 - Preparation pharmaceutique contenant un sel de fluorure - Google Patents

Preparation pharmaceutique contenant un sel de fluorure

Info

Publication number
EP0406279A1
EP0406279A1 EP89903712A EP89903712A EP0406279A1 EP 0406279 A1 EP0406279 A1 EP 0406279A1 EP 89903712 A EP89903712 A EP 89903712A EP 89903712 A EP89903712 A EP 89903712A EP 0406279 A1 EP0406279 A1 EP 0406279A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical preparation
acid
methyl
fluoride salt
oestren
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89903712A
Other languages
German (de)
English (en)
Inventor
Lodewijk Pieter Cornalis Schot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Publication of EP0406279A1 publication Critical patent/EP0406279A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to a pharmaceutical preparation containing a fluoride salt.
  • Such preparations are known, in particular for treating osteoporosis.
  • Fluoride salts such as, for example, NaF and Na 2 PO 3 F stimulate the trabecular bone substance and are therefore suitable for treating osteoporosis.
  • a disadvantage of such preparations is that they cause cortical bone loss and a change in the structure of the cortical bone. As a consequence thereof, the bone becomes more brittle, which has in turn the consequence that more frequent and ready bone fractures, in particular hip fractures, occur.
  • bone-protecting steroids are used to prevent and/or treat osteoporosis and more generally, diseases which are the result of excessively low bone substance.
  • the invention therefore relates to a pharmaceutical preparation containing a fluoride salt and a steroid with the general formula:
  • R 1 H 2 , H(OR 5 ) or 0;
  • R 2 ( ⁇ R 6 ) ( ⁇ OR 7 ) ;
  • R 3 H or (1-4 C)alkyl in position 6 or 7;
  • R 5 H or (1-18 C)acyl
  • R 6 H or (1-4 C) hydrocarbon radical
  • R 7 H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5, 10-position.
  • (1-4 C)Alkyl is understood to mean methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl.
  • R 3 is preferably methyl and is, in addition, preferably situated in the ⁇ -position.
  • R 4 is preferably methyl.
  • (1-18 C) acyl is derived from an organic carboxylic acid containing 1-18 carbon atoms.
  • an organic carboxylic acid containing 1-18 carbon atoms As examples thereof mention may be made of: formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, trimethylacetic acid, valeric acid, caproic acid, capric acid, pelargonic acid, undecylenic acid, lauric acid, palmitic acid, oleic acid, phenylacetic acid, phenylpropionic acid, cyclopentylpropionic acid, cyclohexylcarboxylic acid, cyclooctylacetic acid, benzoic acid, fumaric acid, maleic acid, succinic acid, citric acid.
  • Hydrocarbon radical is understood to mean one of the groups designated above as (1-4 C)alkyl or an unsaturated variant thereof containing 2-4 carbon atoms, such as vinyl, ethynyl, allyl, propargyl, isopropenyl, butynyl or butadienyl.
  • R 6 is preferably ethynyl, R 7 then preferably being H.
  • steroids having the formula I which may be used according to the invention are: 17 ⁇ -ethyl-17 ⁇ -hydroxy- ⁇ 4 -oestrene, 17 ⁇ -hydroxy- ⁇ 4 -oestren-3-one,
  • the pharmaceutical preparations according to the invention can be prepared by known galenical techniques by converting the respective steroid compound and the fluoride salt into a form which is suitable for enteral (for example, oral or rectal, and preferably oral) use.
  • enteral for example, oral or rectal, and preferably oral
  • the steroid compound and the fluoride salt are mixed with or dissolved in a pharmaceutically acceptable carrier.
  • Such preparations are tablets, pills, dragees, pastilles, suppositories, powders, (micro) capsules, emulsions, suspensions and solutions.
  • the pharmaceutically acceptable carriers may be composed of one or more of the following ingredients: starch (for example, potato starch, maize starch), sugars (for example, lactose), lubricants (magnesium stearate, stearic acid), binders (for example, amylopectin, polyvinylpyrrolidone), water, alcohol, glycerol and derivatives thereof, vegetable, animal and mineral oils and fats, fatty alcohols, silicones, lanolins, polyalkylene glycols, cellulose derivatives, silica, dispersants, emulsifiers, surface active substances, antioxidants, preservatives, etc.
  • starch for example, potato starch, maize starch
  • sugars for example, lactose
  • lubricants magnesium stearate, stearic acid
  • binders for example, amylopectin, polyvinylpyrrolidone
  • water for example, alcohol, glycerol and derivatives thereof, vegetable, animal and
  • the preparations according to the invention may suitably be used to prevent and/or treat diseases which occur as a consequence of an excessively low bone substance and in particular, of osteoporosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention se rapporte à une préparation pharmaceutique contenant un sel de fluorure et un stéroïde et est représentée par la formule générale (I), où R1 = H2, H(OR5) ou O; R2 = (alphaR6) (betaOR7); R3 = H ou (1-4 C)alkyle en position 6 ou 7; R4 = (1-4 C)alkyle; R5 = H ou (1-18 C)acyle; R6 = H ou un radical de (1-4 C)hydrocarbure; R7 = H ou (1-18 C)acyle; et les lignes en pointillé indiquent la présence d'une liaison additionnelle dans la position 4,5 ou 5,10.
EP89903712A 1988-03-25 1989-03-24 Preparation pharmaceutique contenant un sel de fluorure Withdrawn EP0406279A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8800749 1988-03-25
NL8800749 1988-03-25

Publications (1)

Publication Number Publication Date
EP0406279A1 true EP0406279A1 (fr) 1991-01-09

Family

ID=19852000

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89903712A Withdrawn EP0406279A1 (fr) 1988-03-25 1989-03-24 Preparation pharmaceutique contenant un sel de fluorure

Country Status (5)

Country Link
EP (1) EP0406279A1 (fr)
JP (1) JPH03503414A (fr)
AU (1) AU3435989A (fr)
DK (1) DK224690A (fr)
WO (1) WO1989009058A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
DE4236090C1 (de) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmazeutische Zubereitung für die Fluoridionen-Versorgung
DK1121375T3 (da) 1998-10-16 2003-08-04 Akzo Nobel Nv (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-on i høj renhedsgrad

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287219A (en) * 1963-08-05 1966-11-22 Charles J Nemanick Method of healing bone fractures

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8909058A1 *

Also Published As

Publication number Publication date
DK224690D0 (da) 1990-09-18
DK224690A (da) 1990-09-18
WO1989009058A1 (fr) 1989-10-05
JPH03503414A (ja) 1991-08-01
AU3435989A (en) 1989-10-16

Similar Documents

Publication Publication Date Title
EP0159739B1 (fr) Stéroides comme immunomodulateurs
US4083973A (en) Pharmaceutical preparation adapted for oral administration
US3859437A (en) Reducing cholesterol levels
JPH0680072B2 (ja) エストリオールエステル、その製法及び該化合物を含有するデポー避妊薬
AU756739B2 (en) Testosterone derivative
EP0037175A1 (fr) Compositions pharmaceutiques
US4117121A (en) Method of increasing bile flow and decreasing lipid levels
JPS62265222A (ja) 細胞膜の脂質構造および機能の修飾法並びにこれに使用する製剤組成物
EP0406279A1 (fr) Preparation pharmaceutique contenant un sel de fluorure
SANANÈS et al. A role for prostaglandins in decidualization of the rat uterus
GB2039217A (en) Anti-inflammatory medicaments comprising glycosides of sterols or spiroketal steroids or esters thereof
US4681875A (en) 3,17 β-estriol diesters, methods of their use, and pharmaceutical preparations containing them
US3639636A (en) Method of lowering serum cholesterol
KR880701731A (ko) 14,17β-에타노-14β-에스트라트리엔 및 에스트라테트라엔 이들의 제조방법 및 이들을 함유하는 약제 조성물
EP0038567B1 (fr) Déazapurine nucléoside, compositions le contenant et son utilisation comme thérapeutique
JPS6145637B2 (fr)
EP0238198A2 (fr) Procédé de modification de la fonction de la structure lipidique et de l'expression des membranes cellulaires et compositions pharmaceutiques pour l'utilisation à cet effet
CA1113926A (fr) Preparation pharmaceutique pour administration orale
JPH09286731A (ja) 乾癬治療薬
EP0297191B1 (fr) Application du N-[(1-éthyl 2-pyrrolidinyl) méthyl] 2-méthoxy 5-sulfamoyl benzamide au traitement de la stérilité
JPS63198630A (ja) 脂質代謝改善剤
AU611290B2 (en) Antihyperlipidemic amines
EP0279565A1 (fr) Médicaments pour le traitement de l'arthrite rhumatoide
JPH0759505B2 (ja) シクロペンテノン類を活性成分とする骨形成促進剤
GB1572488A (en) 1-hydroxy- 4-3-keto-estrenes and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19910702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19921223